D’Anna, Lucio
Searle, Graham
Harvey, Kirsten
Matthews, Paul M.
Veltkamp, Roland
Funding for this research was provided by:
European Union’s Horizon 2020 (754517)
Article History
Received: 8 July 2022
Accepted: 22 March 2023
First Online: 16 May 2023
Declarations
:
: This study was performed in accordance with the Declaration of Helsinki and was approved by the local ethics committee (London – Surrey Borders Research Ethics Committee 17/LO/1041). To be included, patients had to be able to understand the purpose and risks of the study and provide informed consent and authorisation to use protected health information in accordance with national and local subject privacy regulations and according to the local institutional review board’s (IRB’s)/ethics committee’s (EC’s) guidelines.
: Patients have signed a written informed consent for the publication.
: Lucio D’Anna, Graham Searle, Kirsten Harvey report no disclosures. Roland Veltkamp has received fees for consulting and speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Pfizer, Daich Sankyo, Portola, Biogen, Medtronic, Morphosys, Amgen as well as research support from Bayer, Boehringer, BMS, Pfizer, Daiichi Sankyo, Medtronic outside of the present work. Paul M. Matthews has received consultancy fees from Roche, Adelphi Communications, Celgene, Neurodiem and Medscape. He has received honoraria or speakers’ fees from Novartis and Biogen and has received research or educational funds from Biogen, Novartis and GlaxoSmithKline.